[CoViD-19 and chronic diseases: current knowledge, future steps and the MaCroScopio project.]
[CoViD-19 and chronic diseases: current knowledge, future steps and the MaCroScopio project.]
复制标题
DOI：
10.1701/3347.33180
复制
发表时间：
2020-04-01
影响因子：
--
通讯作者：
Maggioni, Aldo
中科院分区：
文献类型：
--
作者：
Martini, Nello;Piccinni, Carlo;Maggioni, Aldo
慢性病和合并症会影响 CoViD-19 感染的风险和病程。流行病学数据和研究显示，不同国家和地区受 CoViD-19 影响的患者的慢性病和多重发病率不同，但他们一致强调其对 CoViD-19 感染的影响。为了保护慢性病和体弱患者，意大利药品管理局已采取措施扩大治疗计划和监测登记册；希望抗糖尿病药物、呼吸系统疾病药物和口服抗凝药物的治疗计划将被废除，因为它们在结果的适当性和可追溯性方面没有提供任何额外的优势。 MacroScopio 项目（慢性病观察站）针对 CoViD-19 紧急情况启动了一条新的研究路径，以促进行政数据流与 CoViD-19 登记册的整合，以实现慢性病背景下的规划和研究目的，并评估该流行病的经济和组织影响。
Chronicity and comorbidity influence the risk of CoViD-19 infection and the course of the disease. Epidemiological data and studies performed show different rates of chronic diseases and multimorbidity among patients affected by CoViD-19 in the various countries and areas, but they consistently stress their impact on CoViD-19 infection. In order to protect chronic and frail patients, the Italian Medicines Agency has taken measures to extend the therapeutic plans and monitoring registers; hopefully, therapeutic plans for antidiabetics, drugs for respiratory diseases and oral anticoagulant drugs will be abolished since they do not offer any additional advantage in terms of appropriateness and traceability of outcomes. The MaCroScopio project (Observatory on Chronic Diseases), regarding the CoViD-19 emergency, has started a new research path to foster the integration of the administrative data flows with the CoViD-19 Registers for planning and research purposes in the context of chronicity, as well as to evaluate the economic and organizational impact of the pandemic.